Apotea Ab · OMXSTO:APOTEA
Apotea Ab — Q1 2026 Earnings Presentation
10 slides from Apotea Ab's earnings presentation, Apr 29, 2026
Slide 1: Q1 2026 presentation
Q1 2026 presentation April 29, 2026 1
Slide 2: Today's presenters
Today’s presenters Pär Svärdson Johan Mårild Sarah Ahnström CEO and Co-founder CFO COO and Deputy CEO Co-founded Apotea in 2012 Joined Apotea in 2022 Joined Apotea in 2019 2
Slide 3: Q1 2026 – Highlights
Q1 2026 – Highlights Q1 figures Strong operating profit and stable 1,937.2 10.5% 5.2% growth Net revenue (SEKm) Net revenue growth EBIT margin 3
Slide 4: Quarterly update
Quarterly update • Improved operating profit, despite increased Net revenue and adjusted EBIT margin* R12M depreciations 7 500 6% 5% • Recently soft launched apotea.no and other 6 500 growth-related initiatives 4% 5 500 3% • Continued to scale up production in Varberg 2% 4 500 1% 3 500 0% Q1 '25 Q2
Slide 5: Growth driven by Rx as well as OTC & traded goods
Growth driven by Rx as well as OTC & traded goods Net revenue development, SEKm Gross margin development, SEKm Rx % of net revenue OTC and traded goods % of net revenue Gross profit Gross margin (%) Services % of net revenue 1000 40,00% 900 35,00% 1,937 1,754 800 30,00% 2.7% 700 27.7% 28.3% 2.3% 549
Slide 6: Improved operating profit and continued good cost control
Improved operating profit and continued good cost control Adjusted EBIT development*, SEKm Operating costs* and D&A, % of net revenue Adj. EBIT Adj. EBIT margin Other OPEX* Personnel cost D&A 22.7% 23.3% 5.3% 5.2% 2.1% 2.8% Q1 '25 Q1 '26 7.5% 7.2% 92.4 92,4 101.3 101,3 13.1% 13.3% Q1 '25 Q1 '26 Q1 '
Slide 7: Stable operating cash flow
Stable operating cash flow Cash flow development, SEKm Net working capital, SEKm Cash flow from operating activities Capex Other current assets* Accounts receivables Inventory Other current liabilities* Accounts payables 123,2 123.2 116.7 116,7 112.5 112,5 352 352 259 108 78 355 81 371 355 613 652 8
Slide 8: Solid net cash position
Solid net cash position Return on capital employed (ROCE) Net debt (excl. IFRS 16) development, SEKm Interest-bearing debt (excl. IFRS16) Net indebtedness/EBITDA (excl. IFRS16) Cash and cash equivalents 0.2x -0.2x 33.9% 61 26.7% 82 - -21 -105 -105 Q1 '25 Q1 '26 Mar '25 Mar '26 • ROCE impacted by the
Slide 9: Our focus ahead
Our focus ahead Continue shaping the pharmacy of tomorrow and improve customer offering and efficiency • Focus on growth • apotea.no • Evaluate and launch growth-related initiatives and investments • Continue to scale up production in Varberg • Navigate times of uncertainty 9
Slide 10: Q&A
Q&A 10